The Expanding Landscape of GLP-1 Receptor Agonists: Beyond Weight Management to Cardiometabolic and Neuroprotective Applications
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes (T2D) and obesity, primarily through their glucose-lowering and weight-reducing effects. However, emerging evidence suggests their therapeutic potential extends far beyond […]
